Laurus Labs reported strong Q1 FY27 results with revenues at INR 2,026 Cr (+29% YoY), EBITDA at INR 644 Cr (31.8% margin), and PAT at INR 368 Cr.

CDMO business surged 69% to INR 835 Cr, with 55% from commercial supplies.

Affordable Medicines grew 10% to INR 1,156 Cr.

Management is confident in sustained growth, increasing FY27 capex to INR 2,000 Cr for capacity expansion driven by customer demand.

The company is strategically investing in new modalities like peptides, ADCs, and gene therapy for long-term value creation.

ROCE now stands at 19%, with a goal for asset turnover above 1.0.